Eletriptan 40 mg and 80 mg tablets were listed on the Pharmaceutical Benefits Scheme as authority required (streamlined) on 1 October 2010 (Table 1).1,2 Eletriptan has been available overseas for several years.3 Avoid use within 48 hours of cytochrome P450 3A4 inhibitors (e.g. ketoconazole, erythromycin, protease inhibitors), as this causes increased plasma concentrations of eletriptan.4

All triptans are effective for migraine5,6 but individual response cannot be predicted.7 If the first triptan fails, try another.

Table 1.
Summary of triptans listed on the PBS8

Generic Brand names PBS listing*
Authority required (streamlined) Authority required Special patient contribution








Imigran Sumagran



* Restricted to people with past migraines that have usually failed to respond to analgesics
Unless exempted, this is payable in addition to the relevant patient copayment for concessional and general patients. Exemptions may be granted for people where adverse events, drug interactions, patient confusion or adverse clinical consequences preclude the use of other triptans. Refer to www.pbs.gov.au for details


  1. Pharmaceutical Benefits Advisory Committee. Positive recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2010 relating to the listing of drugs on the Pharmaceutical Benefits Scheme (PBS). Canberra: Australian Government Department of Health and Ageing, 2010. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-mar10-positive (accessed 15 June 2010).
  2. Pharmaceutical Benefits Advisory Committee. Public summary document for eletriptan hydrobromide tablet 40 mg and 80 mg (Relpax). Canberra: Australian Government Department of Health and Ageing, 2010. http://www6.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-elitriptan-mar10 (accessed 19 July 2010).
  3. Anonymous. Eletriptan; me-too triptan for migraine attacks. Prescrire International 2003;12:97.
  4. Pfizer Australia Pty Limited. Relpax product information. 11\u00a0March 2010.
  5. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633\u201358. [PubMed]
  6. Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache 2007;47:1152\u201368. [PubMed]
  7. National Prescribing Centre. The management of migraine. MeReC Bulletin 13:(2). Liverpool: National Health Service, 2002. http://www.npc.co.uk/ebt/merec/pain/migraine/resources/merec_bulletin_vol13_no2.pdf (accessed 15 January 2010).
  8. Department of Health and Ageing. PBS for Health Professionals. Canberra, 2010. www.pbs.gov.au (accessed 15 June 2010).